Sort
23,748 grants matching “melanoma”
Tumor Organoid-Mediated Drug Testing and Clonality Analysis in Peritoneal Surface Disease of Intestinal Origin
$494,277Konstantinos Votanopoulos · Wake Forest University Health Sciences · R01 · FY2023 · CA
Ultrasmall particle-based solutions for inducing ferroptosis and improving anti-tumor immune responses in cancer
$494,251Michelle S Bradbury · Weill Medical Coll Of Cornell Univ · R01 · FY2024 · CA
Risk Factors for Nevus Development in Children
$494,226Lori A Crane · University Of Colorado Denver · R01 · FY2013 · CA
NGF recruits nerve fibers to reprogram an immunosuppressive microenvironment in melanoma
$494,201Xiao-Fan Wang · Duke University · R01 · FY2022 · CA
The Development of Thermally-activated Metalloenediynes for Cancer Therapy
$494,172Joseph R Dynlacht · Indiana University Indianapolis · R01 · FY2018 · CA
Unraveling the Impact of Extracellular Vesicle-Loaded FXR1 mRNA on Re-educating Cancer Microenvironment
$494,160Pradeep Chaluvally-Raghavan · Medical College Of Wisconsin · R01 · FY2025 · CA
Tumor Organoid-Mediated Drug Testing and Clonality Analysis in Peritoneal Surface Disease of Intestinal Origin
$494,107Konstantinos Votanopoulos · Wake Forest University Health Sciences · R01 · FY2025 · CA
Gasdermin E and pyroptosis in cancer
$493,985Judy Lieberman · Boston Children'S Hospital · R01 · FY2022 · CA
Gasdermin E and pyroptosis in cancer
$493,985Judy Lieberman · Boston Children'S Hospital · R01 · FY2023 · CA
Targeting telomerase for melanoma therapeutics
$493,948Emmanuel Skordalakes · Wistar Institute · R01 · FY2016 · CA
Role of metabolic crosstalk in determining immunity during tumor progression
$493,895Ana C Anderson · Brigham And Women'S Hospital · R01 · FY2025 · CA
Understanding and Overcoming Resistance to BRAF/MEK Kinase Inhibitors in Melanoma
$493,786Arjun Raj · University Of Pennsylvania · R01 · FY2023 · CA
Understanding and Overcoming Resistance to BRAF/MEK Kinase Inhibitors in Melanoma
$493,785Arjun Raj · University Of Pennsylvania · R01 · FY2022 · CA
Molecular Aspects of Antitumor Antibodies
$493,699Jeffrey Victor Ravetch · Rockefeller University · R01 · FY2012 · CA
Protein Structure, Stability, and Amyloid Formation
$493,654Ruth Nussinov · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Identifying Clusters of Vision and Eye Health Problems Using Secondary Surveillance Data
$493,642David B Rein · National Opinion Research Center · R21 · FY2025 · EY
Novel DGKalpha inhibitors and immunotherapy for GBM and melanoma brain metastasis
$493,581Benjamin W. Purow · University Of Virginia · R01 · FY2015 · CA
Novel DGKalpha inhibitors and immunotherapy for GBM and melanoma brain metastasis
$493,581Benjamin W. Purow · University Of Virginia · R01 · FY2016 · CA
Novel DGKalpha inhibitors and immunotherapy for GBM and melanoma brain metastasis
$493,581Benjamin W. Purow · University Of Virginia · R01 · FY2014 · CA
Role of Formylpeptide Receptors in Host Defense
$493,555Ji Ming Wang · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Exploiting a novel regulator of immunometabolism to enhance immunotherapy
$493,535Edward John Usherwood · Dartmouth College · R01 · FY2022 · CA
Exploiting a novel regulator of immunometabolism to enhance immunotherapy
$493,535Edward John Usherwood · Dartmouth College · R01 · FY2025 · CA
Project 1: Identifying new therapeutic avenues to selectively target tumors with uncontrolled mTORC1 activation
$493,468David J. Kwiatkowski · Brigham And Women'S Hospital · P01 · FY2025 · CA
Evaluation of Immune-based Combinations in Prostate Cancer
$493,445Ravi Madan · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
TECHNETIUM AND RHENIUM IN NUCLEAR MEDICINE
$493,378Harvard University (Medical School) · R01 · FY2002 · CA